AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.

2604 Background: AB928, a selective, small-molecule A2aR/A2bR antagonist, potently blocks the immunosuppressive effects of high adenosine concentrations in the tumor microenvironment. Preclinically, combining adenosine receptor inhibition with either chemotherapy or anti-PD-1 resulted in greater tumor control, suggesting AB928 may have additive activity when paired with either of these agents in cancer pts. Methods: Three dose-escalation (3+3 design) studies are assessing the safety, pharmacokinetics (PK), pharmacodynamics, and clinical activity of increasing doses of AB928 (75, 150, 200 mg orally once daily) in combination with: standard pegylated liposomal doxorubicin in triple-negative breast cancer (TNBC) and ovarian cancer (OC); standard mFOLFOX6 in gastroesophageal cancer (GEC) and colorectal cancer (CRC); and AB122 (240 mg every 2 weeks) in various advanced tumors. Following identification of the recommended phase 2 dose of AB928 in combination with chemotherapy or AB122 in dose escalation, the following tumor cohorts may be expanded (15-40 pts/cohort) to further test the combinations: TNBC and OC, GEC and CRC, and renal cell carcinoma. Results: As of 01Feb2019, 9 pts were treated across the 3 studies, and time on treatment ranged from 1-182 days (table). Overall, AB928 combination therapy was well tolerated. Two pts underwent post-baseline disease assessment; both had stable disease. Preliminary data indicate that AB928 PK and adenosine receptor coverage in cancer pts are similar to what was previously assessed in healthy volunteers. AB122 PK and PD-1 coverage are equally unaffected by AB928 co-administration. Updated data, including biomarker data, will be presented at the meeting. Conclusions: Early results showed a favorable safety profile of AB928 combination therapy. All 3 studies are actively recruiting pts. Clinical trial information: NCT03719326; NCT03720678; NCT03629756. [Table: see text]

• Publication year

  2019

• Venue

  Journal of Clinical Oncology

• Publication date

  2019-05-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2019.37.15_SUPPL.2604
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Xathine unveiled: Bridging CD4+ T cell and stress-induced disorders through purine metabolism

  2025cites this paper
• Potential of Adora2b as an immunotherapeutic target for gastric cancer

  2025cites this paper
• Development of nano-immunotherapy for cancer treatment: achievements and scopes

  2023cites this paper
• Targeting regulatory T cells by E7777 enhances CD8 T-cell–mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models

  2023cites this paper
• Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment

  2023cites this paper
• Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors

  2023cites this paper
• The Role of Cluster of Differentiation 39 (CD39) and Purinergic Signaling Pathway in Viral Infections

  2023cites this paper
• The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies

  2023cites this paper
• A2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models

  2022cites this paper
• Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence

  2022cites this paper
• The evolutionary legacy of immune checkpoint inhibitors.

  2022cites this paper
• Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death

  2022cites this paper
• Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent GPCR ligands.

  2022cites this paper
• Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors

  2022cites this paper
• Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development.

  2022cites this paper
• A macrophage membrane-coated mesoporous silica nanoplatform inhibiting adenosine A2AR via in situ oxygen supply for immunotherapy.

  2022cites this paper
• Update of early phase clinical trials in cancer immunotherapy

  2021cites this paper
• Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development

  2021cites this paper
• Adenosine receptor antagonists: Recent advances and therapeutic perspective.

  2021cites this paper
• Targeting regulatory T cells in anti‐PD‐1/PD‐L1 cancer immunotherapy

  2021cites this paper
• Next generation of immune checkpoint inhibitors and beyond

  2021influential citation
• Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches.

  2020cites this paper
• Emerging therapeutic agents for advanced non-small cell lung cancer

  2020cites this paper
• CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers

  2020cites this paper
• Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

  2020cites this paper
• Adenosine and adenosine receptors in colorectal cancer.

  2020cites this paper
• Targeting the A2AR in cancer; early lessons from the clinic.

  2020cites this paper
• Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

  2019cites this paper
• The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy

  2018cites this paper